{"id":"NCT03336619","sponsor":"Romark Laboratories L.C.","briefTitle":"A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza","officialTitle":"A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-01-17","primaryCompletion":"2019-04-17","completion":"2019-04-17","firstPosted":"2017-11-08","resultsPosted":"2022-06-28","lastUpdate":"2022-06-28"},"enrollment":1030,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Influenza"],"interventions":[{"type":"DRUG","name":"Nitazoxanide","otherNames":["NTZ","NT-300"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Nitazoxanide","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Trial to evaluate efficacy and safety of nitazoxanide (NTZ) in the treatment of uncomplicated influenza.","primaryOutcome":{"measure":"Time From First Dose to Symptom Response","timeFrame":"Up to 21 days","effectByArm":[{"arm":"Nitazoxanide","deltaMin":155.1,"sd":null},{"arm":"Placebo","deltaMin":153.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.3765"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":38,"countries":["United States","Australia","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":515},"commonTop":["Chromaturia","Diarrhoea","Nausea"]}}